Our results showed that extracellular GP73 and PKM2 synergistically attenuated the anti-tumor efficiency of sorafenib, suggesting that high secretion of GP73 and PKM2 can lead to resistance to sorafenib. Here, GOLM1 is linked to neoplasm.